News
Sources also say that the administration plans to split CBER in two, with one of the section focused entirely on vaccines.
In a striking bipartisan move, the Senate Appropriations Committee voted 26-3 to boost the NIH’s budget by $400 million — rejecting the Trump administration’s proposed $17 billion cut and sweeping ...
Dr George Tidmarsh, a former pharmaceutical executive who joined the FDA this month, will take over Prasad’s role temporarily.
The FDA has denied that it plans to combine the Center for Drug Evaluation and Research and Center for Biologics Evaluation ...
Parents of boys with Duchenne muscular dystrophy weigh in on drug innovation and medical regulation.
Prasad, a longtime critic of the FDA’s leniency in drug approvals, joined the agency in May. WASHINGTON — The Food and Drug ...
Two major health agencies are facing leadership reshuffles, with the resignations of the FDA’s Vinay Prasad and NICE’s Dr Sam Roberts.
Vinay Prasad’s ouster as the Food and Drug Administration’s top vaccine and gene therapy regulator came after frustration ...
This week on "The Readout LOUD," STAT's biotech reporters parse what Vinay Prasad's ouster means for biotech and the FDA.
PTC Therapeutics faces pivotal FDA decisions for approvals that could potentially transform their long-term revenues. Click ...
From the meme stock revival to Trump's Fed feud, Peter Hodson looks at some of the summer's more bizarre trends ...
Dr. Vinay Prasad, the chief scientific officer at the Food and Drug Administration, has resigned after only three months in the position.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results